A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2017
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Medipost
- 18 Apr 2017 Planned number of patients changed from 42 to 45.
- 18 Apr 2017 Planned End Date changed from 1 Feb 2018 to 1 Jul 2019.
- 18 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2019.